CLINICAL_TRIALS
trial_result
· 2019-02-12
Clinical Trial Update: High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma [Phase 2]
Summary
Phase 2 trial evaluating high-dose interleukin-2 followed by intermittent low-dose temozolomide in melanoma; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Milton S. Hershey Medical Center | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2019-02-12